Prostate cancer is the third most common malignancy in men in England and Wales, with over 10 000 new cases and 8000 deaths from the disease every year (OPCS, 1993) . Over half the patients present with locally advanced and/or metastatic disease, and can be treated by palliative measures only. In addition, once early tumours are detected, prognosis is largely unpredictable by current investigative methods. Clinicians are unable to predict disease progression and to inform the patient whether his tumour is likely to progress, or whether any form of treatment will alter the outcome. New criteria to define the aggressive and metastatic potential of early prostate cancer are needed, particularly in view of the recent controversies and evidence from North American studies questioning the benefits of radical surgery over observation in early stage prostatic adenocarcinoma (Fleming et al., 1993; Lu-Yao et al., 1993; Chodak et al., 1994) . Furthermore, even in cases where the disease appears to be confined to the prostate, cancers are understaged in over 50% of cases, with resulting positive surgical margins, extracapsular extension and potential treatment failure (Epstein et al., 1993) .
The formation of metastasis is a significant, ratedetermining event in the progression of cancer. It is a complex, non-random phenomenon involving a cascade of multisequential events, including tumour cell detachment from the primary lesion into the blood and lymphatic channels, survival of a selected population of malignant cells in a hostile environment, extravasation at a chosen site and the final formation of a secondary deposit (Poste and Fidler, 1980) .
In an attempt to isolate circulating tumour cells in prostate cancer patients before their actual deposition at a distant site and metastasis formation, we have previously demonstrated the presence of circulating prostate-specific antigen (PSA)-positive cells using monoclonal antibody (MAb) staining for PSA and flow cytometric analysis (Hamdy et al., 1992 conjugated goat anti-mouse negative control was included. DNA ploidy status was measured by flow cytometry (Ortho Diagnostic Orthocyte), using propidium iodide (DNA CycleTest, Becton-Dickinson, Cowley, UK) and at least 10 000 cells analysed.
Oligonucleotide primers and probes Oligonucleotide primers and probes were designed and checked for specificity using the SEQNET facility (SERC, Daresbury Laboratory, UK). The sequences used were as follows:
Antisense PCR primer (exon 3):
5'-ACTCCTCTGGTTCAATGCTG-3' Sense PCR primer (exon 2):
5'-TCATCCTGTCTCGGATTGTC-3' Exon 3 probe:
5'-CCGACCCAGCAAGATCACGC-3' (Table I) showed an unusual scatter distribution for PBMCs, and a cell population was detected of similar or greater size to the monocyte population by normal scatter analysis (Figure 1 ). Detection of PSA mRNA by RT-PCR Following the BPH spiking experiment under the conditions outlined, we were able to detect one PSA-positive cell per 104 PBMCs by RT-PCR (two titrations, cDNA samples run at least twice). The RT-PCR was 100-fold more sensitive than the flow cytometric analysis threshold of one PSA-positive cell per 100 PBMCs. Positive controls (BPH tissue) and PBMC samples from negative controls and patients were reverse transcribed and subjected to PCR amplification using PSA-specific primer sequences. Following gel electrophoresis and ethidium bromide staining, a PCR product corresponding to a 426 bp fragment was detectable in all positive controls, but not in the negative controls or patient PBMC samples. For more sensitive detection, the gels were blotted and hybridised with the antisense oligonucleotide probe corresponding to a unique sequence of exon 3 (see Materials and methods) . This allowed the detection of a band of 426 bp in a single patient sample (Figure 2b ). This sample was obtained from patient 8 (Table I) who had an aggressive, poorly differentiated locally advanced and metastatic tumour (T4NxM 1 Gleason score 9) which did not respond to hormone manipulation, and also demonstrated an unusual PBMC scatter analysis (illustrated in Figure la) . RT-PCR for LNCaP cells was carried out as a second positive control with 1-5 Mg of total RNA. Products were detected for all RNA concentrations. LNCaP cells and tissue extracts were shown to express up to three bands; controls for PBMCs, cDNA synthesis, PCR and RNAzol were all negative. Figure  2a shows negative (female PBMCs), positive controls (LNCaP) and negative patients.
Discussion
The detection of circulating tumour cells in cancer patients is not by any means a new phenomenon. Indeed, several . ' * :
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; .e :* * * -. previous studies, some dating back over half a century, have elegantly demonstrated the presence of circulating malignant cells in the peripheral blood of patients with advanced disease (Warren and Gates, 1936; Engell, 1955; Fidler, 1970; Schwartz et al., 1995) , without the help of current sophisticated and molecular biology techniques. Previous studies in animals have shown that metastasis does not rely on the random survival of cells released from the primary tumour, but from the selective growth of specialised subpopulations of highly metastatic cells endowed with properties which will allow them successfully to complete each step of the metastatic cascade (Fidler, 1970; Fidler and Kripke, 1977 
